Australian Clinical Labs Ltd (AU:ACL)
ASX:ACL
Top Page
Australian Clinical Labs Ltd
(Sydney:ACL)
Select Model
Select Model
Rating:59Neutral
Price Target:
AU$2.00
▼(-0.50% Downside)
Action:DowngradedDate:02/17/26
Overall score is held back primarily by weak technicals (price below all major moving averages with negative MACD), partially offset by solid cash flow generation and an attractive valuation (moderate P/E and high dividend yield). Financial leverage remains a key risk despite decent ROE and improving gross margin.
Positive Factors
Strong cash generation
Consistent FCF growth and high cash conversion (OCF/NI 0.84, FCF/NI 0.95) indicate the business reliably turns accounting earnings into cash. Durable cash generation underpins dividends, capex funding, debt servicing and strategic flexibility over the next several quarters.
Negative Factors
High financial leverage
A debt-to-equity ratio of 1.69 creates structural vulnerability: higher interest burden and less financial flexibility. In a lower-growth or reimbursement-pressured environment, leverage magnifies downside risk and can constrain investments or require cash for servicing rather than growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Consistent FCF growth and high cash conversion (OCF/NI 0.84, FCF/NI 0.95) indicate the business reliably turns accounting earnings into cash. Durable cash generation underpins dividends, capex funding, debt servicing and strategic flexibility over the next several quarters.
Read all positive factors
Australian Clinical Labs Ltd (ACL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$380.08M
Dividend Yield4.6%
Average Volume (3M)867.30K
Price to Earnings (P/E)23.9
Beta (1Y)0.93
Revenue Growth6.73%
EPS Growth37.16%
CountryAU
Employees4,900
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.07
Shares Outstanding188,157,840
10 Day Avg. Volume799,589
30 Day Avg. Volume867,296
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)3.09
Price to Sales (P/S)0.71
P/FCF Ratio3.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.33Price Target Upside15.92% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.17
Revenue Forecast (FY)AU$736.49M
Australian Clinical Labs Ltd Business Overview & Revenue Model
Company Description
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier...
How the Company Makes Money
ACL makes money primarily by performing diagnostic pathology tests and charging for those services. Its revenue model is largely fee-for-service: when a clinician requests a pathology test (e.g., blood, urine, tissue/cytology and other laboratory ...
Australian Clinical Labs Ltd Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
58
Neutral
Cash Flow
72
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 733.52M | 741.27M | 689.73M | 692.10M | 989.30M | 641.31M |
| Gross Profit | 209.96M | 270.86M | 138.45M | 566.02M | 781.71M | 521.73M |
| EBITDA | 133.59M | 81.36M | 169.65M | 184.93M | 372.75M | 196.67M |
| Net Income | 26.31M | 32.43M | 23.93M | 35.90M | 178.24M | 60.37M |
Balance Sheet | ||||||
| Total Assets | 562.50M | 574.84M | 593.06M | 578.91M | 628.04M | 474.70M |
| Cash, Cash Equivalents and Short-Term Investments | 23.14M | 22.12M | 26.84M | 20.59M | 27.51M | 36.28M |
| Total Debt | 453.61M | 290.38M | 308.90M | 316.32M | 262.38M | 294.26M |
| Total Liabilities | 411.46M | 402.86M | 415.30M | 406.24M | 395.49M | 392.79M |
| Stockholders Equity | 150.57M | 171.35M | 177.53M | 172.42M | 232.44M | 81.90M |
Cash Flow | ||||||
| Free Cash Flow | 156.69M | 174.39M | 153.09M | 136.75M | 262.83M | 144.36M |
| Operating Cash Flow | 164.57M | 182.80M | 159.59M | 143.68M | 284.09M | 153.86M |
| Investing Cash Flow | -8.32M | -8.89M | -7.25M | -12.18M | -72.04M | -6.08M |
| Financing Cash Flow | -154.65M | -178.74M | -146.14M | -137.88M | -220.91M | -147.37M |
Australian Clinical Labs Ltd Technical Analysis
Negative
2.01
Price Trends
2.18
Negative
2.43
Negative
2.50
Negative
Market Momentum
-0.03
Negative
41.16
Neutral
32.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACL, the sentiment is Negative. The current price of 2.01 is below the 20-day moving average (MA) of 2.02, below the 50-day MA of 2.18, and below the 200-day MA of 2.50, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 41.16 is Neutral, neither overbought nor oversold. The STOCH value of 32.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ACL.
Australian Clinical Labs Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$9.75B | 10.64 | 6.39% | 4.69% | 9.44% | -0.37% | |
59 Neutral | AU$380.08M | 23.92 | 16.35% | 4.60% | 6.73% | 37.16% | |
55 Neutral | AU$838.92M | 26.42 | 2.05% | 2.65% | 33.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$370.33M | -5.40 | -67.21% | ― | -23.02% | 33.11% |
* Healthcare Sector Average
AU:ACL
Australian Clinical Labs Ltd
2.01
-0.84
-29.57%
AU:HLS
Healius Limited
0.51
-0.47
-48.17%
AU:SHL
Sonic Healthcare Limited
20.09
-4.07
-16.85%
AU:IDX
Integral Diagnostics Ltd.
2.25
<0.01
0.13%
Australian Clinical Labs Ltd Corporate Events
Australian Clinical Labs Reports Daily Progress on On‑Market Share Buy‑Back
Mar 23, 2026
Australian Clinical Labs has updated the market on its ongoing on‑market share buy‑back of ordinary fully paid shares. The company reported that it had repurchased a cumulative 6,388,208 shares prior to the latest trading day and bough...
Australian Clinical Labs Cancels Shares Following On-Market Buy-Back
Mar 23, 2026
Australian Clinical Labs has cancelled 573,748 fully paid ordinary shares following an on-market share buy-back, as disclosed in its latest capital notification to the exchange. The move reduces the company’s issued capital base and may incr...
Australian Clinical Labs Updates Progress of On-Market Share Buy-Back
Mar 22, 2026
Australian Clinical Labs has continued its on-market share buy-back program, repurchasing a total of 6,138,208 ordinary fully paid shares prior to the latest reporting date. The company bought back a further 250,000 shares on the previous trading ...
Australian Clinical Labs Continues On-Market Share Buy-Back Program
Mar 19, 2026
Australian Clinical Labs has an on-market share buy-back in place for its ordinary fully paid shares on the ASX, as part of a capital management program first notified in October 2025. The latest daily update shows that the company repurchased 81,...
Australian Clinical Labs Updates Market on Progress of On-Market Share Buy-Back
Mar 17, 2026
Australian Clinical Labs has provided an updated notification to the ASX on its ongoing on-market share buy-back of ordinary fully paid shares. The latest daily report, dated 18 March 2026, confirms that the company repurchased 80,063 shares in th...
Australian Clinical Labs Updates Market on Ongoing Share Buy‑Back Activity
Mar 16, 2026
Australian Clinical Labs has been conducting an on‑market share buy‑back of its ordinary fully paid shares, as part of a previously announced capital management program first notified in October 2025. The company reported that, as of t...
Australian Clinical Labs Updates Market on Progress of On‑Market Share Buy-Back
Mar 11, 2026
Australian Clinical Labs Limited has updated the market on its ongoing on‑market share buy-back program for its ordinary fully paid shares listed under the ASX code ACL. The company reported that a total of 5,690,543 shares had been repurcha...
Australian Clinical Labs Cancels Over 1 Million Shares in On‑Market Buy‑Back
Mar 11, 2026
Australian Clinical Labs has cancelled 1,012,269 ordinary fully paid shares following an on‑market buy‑back completed on 9 March 2026. The reduction in issued capital through the buy‑back may enhance earnings per share and signal...
Australian Clinical Labs Updates Market on Ongoing Share Buy-Back
Mar 10, 2026
Australian Clinical Labs Ltd has provided an updated notification to the ASX regarding its ongoing on-market share buy-back of ordinary fully paid shares. The company reported that, as of 11 March 2026, it has repurchased a cumulative 5,607,148 sh...
Australian Clinical Labs Updates Market on Ongoing Share Buy-Back
Mar 9, 2026
Australian Clinical Labs Limited has provided an update on its on-market share buy-back program for its ordinary fully paid shares traded under the ASX code ACL. The company reported that, as of the latest notification dated 10 March 2026, it had ...
Australian Clinical Labs Reports Ongoing On‑Market Share Buy‑Back Activity
Mar 5, 2026
Australian Clinical Labs Ltd, a pathology and diagnostic services provider listed on the ASX, is continuing to execute its on-market share buy-back program for its ordinary fully paid shares. The company operates in the Australian healthcare secto...
Australian Clinical Labs Service Rights Lapse Reduces Potential Equity Pool
Mar 4, 2026
Australian Clinical Labs has reported a change in its issued capital following the lapse of 125,145 service rights, identified under the ASX security code ACLAD. These rights ceased on 9 January 2026 after the conditions attached to them were not ...
Australian Clinical Labs Updates Market on Progress of On-Market Share Buy-Back
Mar 3, 2026
Australian Clinical Labs Ltd has provided an updated notification to the ASX regarding its ongoing on-market share buy-back program for its ordinary fully paid shares. The company reported that a total of 5,113,904 securities had been repurchased ...
Australian Clinical Labs Updates Daily On-Market Share Buy-Back Activity
Mar 2, 2026
Australian Clinical Labs has disclosed an update to its on-market share buy-back program for its ordinary fully paid shares listed on the ASX under ticker ACL. The filing notes that, as of the latest reporting date, the company continues to execut...
Australian Clinical Labs Updates Progress on On‑Market Share Buy‑Back
Mar 1, 2026
Australian Clinical Labs has provided an updated notification on its on‑market share buy‑back program for its fully paid ordinary shares. The announcement records that, as of the latest daily update, the company has bought back 100,000...
Australian Clinical Labs Cancels 900,000 Shares in On‑Market Buy‑Back
Feb 27, 2026
Australian Clinical Labs Limited has cancelled 900,000 fully paid ordinary shares as part of an on‑market buy‑back, effective 24 February 2026. The reduction in issued capital signals an active capital management program that may enhan...
Australian Clinical Labs Reports Daily Progress of On-Market Share Buy-Back
Feb 26, 2026
Australian Clinical Labs has provided an updated notification on its on-market share buy-back program for its fully paid ordinary shares. The company reported that, as of the latest daily update, it had repurchased a cumulative total of 4,829,786 ...
Citi Group Entities Exit Substantial Holder Position in Australian Clinical Labs
Feb 25, 2026
Citigroup Global Markets Australia Pty Limited and related Citi group entities have ceased to be substantial holders in Australian Clinical Labs, after reducing their relevant interest in the company’s ordinary fully paid shares. The change ...
Australian Clinical Labs Updates Progress of On‑Market Share Buy‑Back
Feb 25, 2026
Australian Clinical Labs Limited has provided an update on its on‑market share buy‑back program for its ordinary fully paid shares. The company reported that a total of 4,670,516 shares had been repurchased before the previous trading ...
Australian Clinical Labs Continues On‑Market Share Buy‑Back Program
Feb 23, 2026
Australian Clinical Labs has continued its on‑market share buy‑back program, repurchasing a total of 4,470,516 ordinary fully paid shares prior to the latest trading day under the existing mandate first notified in October 2025. The co...
Australian Clinical Labs Updates Market on Ongoing Share Buy-Back
Feb 22, 2026
Australian Clinical Labs has continued its on-market share buy-back program, updating the market with a daily notification to the ASX. The company reported that it has repurchased a total of 4,270,516 ordinary fully paid shares prior to the latest...
Australian Clinical Labs Director Sarah Butler Acquires Indirect Shareholding
Feb 20, 2026
Australian Clinical Labs has disclosed a change in director Sarah Butler’s relevant interests, with Butler acquiring an indirect stake in the company through a trust structure. The transaction signals increased alignment between the director...
Australian Clinical Labs Lifts Total On‑Market Buy‑Back to Over 4 Million Shares
Feb 19, 2026
Australian Clinical Labs has continued its on‑market share buy‑back program, repurchasing a further 200,000 ordinary fully paid shares on 19 February 2026. This lifts the total number of shares bought back under the program to 4,070,51...
Australian Clinical Labs Sets Investor Webinar for 1H26 Results
Jan 30, 2026
Australian Clinical Labs will release its financial and operating results for the half year ended 31 December 2025 on 16 February 2026 and will brief investors via a Zoom webinar hosted by CEO Melinda McGrath and CFO Matt Cordingley. The company w...
Australian Retirement Trust Ceases to Be Substantial Holder in Australian Clinical Labs
Jan 23, 2026
Australian Retirement Trust Pty Ltd has notified Australian Clinical Labs Limited that it has ceased to be a substantial shareholder in the company as of 21 January 2026, according to a change in relevant interests disclosed under the Corporations...
Australian Ethical Exits Substantial Holder Position in Australian Clinical Labs
Jan 19, 2026
Australian Ethical Investment Limited has notified the market that it has ceased to be a substantial shareholder in Australian Clinical Labs Limited, as formalised in a Form 605 lodged with the ASX. The change reduces Australian Ethical’s si...
Australian Clinical Labs Cancels 200,000 Shares Under On‑Market Buy-Back
Dec 28, 2025
Australian Clinical Labs Limited has cancelled 200,000 fully paid ordinary shares as part of an on‑market share buy-back, effective 22 December 2025. The reduction in issued capital reflects the company’s ongoing capital management str...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.